| http://dbpedia.org/ontology/abstract
|
Brodalumab (v USA pod názvem Siliq, v Evropě Kyntheum) je lidská monoklonální protilátka určená k léčbě zánětlivých onemocnění.V únoru 2017 byl Brodalumab schválen FDA pro léčbu středně těžké až těžké (lupénky) u lidí, jejichž předchozí léčba selhala.
, برودالوماب هو جسم مضاد وحيد النسيلة مصمم لعلاج أمراض التهابية طورته آمجن.
, Le brodalumab est un anticorps monoclonal … Le brodalumab est un anticorps monoclonal ciblant le récepteur A de l'interleukine 17 (IL-17RA). Il agit comme antagoniste des récepteurs à l'IL-17 comparativement aux autres inhibiteurs de l'IL-17, qui eux vont agir sur l'IL-17 et non sur son récepteur en la neutralisant. Il est aujourd'hui approuvé dans différentes juridictions dans le traitement du psoriasis modéré à sévère.e traitement du psoriasis modéré à sévère.
, Brodalumab, sold under the brand name Sili … Brodalumab, sold under the brand name Siliq in the US and Kyntheum in the EU, is a human monoclonal antibody designed for the treatment of inflammatory diseases. In February 2017, it received US FDA approval to treat moderate to severe plaque psoriasis in people who have not improved with other treatments.o have not improved with other treatments.
, Бродалумаб (brodalumab) — лекарственный препарат, моноклональное антитело. Одобрен для применения: США (февраль 2017 года).
|
| http://dbpedia.org/ontology/alternativeName
|
Siliq, Kyntheum, Lumicef
|
| http://dbpedia.org/ontology/casNumber
|
1174395-19-7
|
| http://dbpedia.org/ontology/drugbank
|
DB11776
|
| http://dbpedia.org/ontology/fdaUniiCode
|
6ZA31Y954Z
|
| http://dbpedia.org/ontology/kegg
|
D10061
|
| http://dbpedia.org/ontology/wikiPageExternalLink
|
https://druginfo.nlm.nih.gov/drugportal/name/brodalumab +
|
| http://dbpedia.org/ontology/wikiPageID
|
33023911
|
| http://dbpedia.org/ontology/wikiPageLength
|
8806
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1124010770
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Interleukin_17_receptor_A +
, http://dbpedia.org/resource/Interleukin-17_receptor +
, http://dbpedia.org/resource/FDA +
, http://dbpedia.org/resource/AstraZeneca +
, http://dbpedia.org/resource/Interleukin_17 +
, http://dbpedia.org/resource/Ixekizumab +
, http://dbpedia.org/resource/Category:Amgen +
, http://dbpedia.org/resource/Plaque_psoriasis +
, http://dbpedia.org/resource/Biologics_license_application +
, http://dbpedia.org/resource/LEO_Pharma +
, http://dbpedia.org/resource/Valeant_Pharmaceuticals +
, http://dbpedia.org/resource/Amgen +
, http://dbpedia.org/resource/Monoclonal_antibody +
, http://dbpedia.org/resource/Primary_endpoint +
, http://dbpedia.org/resource/Ustekinumab +
, http://dbpedia.org/resource/Kyowa_Hakko_Kirin +
|
| http://dbpedia.org/property/atcPrefix
|
L04
|
| http://dbpedia.org/property/atcSuffix
|
AC12
|
| http://dbpedia.org/property/c
|
6372
|
| http://dbpedia.org/property/casNumber
|
1174395
|
| http://dbpedia.org/property/chemspiderid
|
none
|
| http://dbpedia.org/property/dailymedid
|
Brodalumab
|
| http://dbpedia.org/property/drugbank
|
DB11776
|
| http://dbpedia.org/property/h
|
9840
|
| http://dbpedia.org/property/kegg
|
D10061
|
| http://dbpedia.org/property/legalCa
|
Rx-only
|
| http://dbpedia.org/property/legalEu
|
Rx-only
|
| http://dbpedia.org/property/legalStatus
|
Rx-only
|
| http://dbpedia.org/property/legalUs
|
Rx-only
|
| http://dbpedia.org/property/licenceUs
|
Brodalumab
|
| http://dbpedia.org/property/mabType
|
mab
|
| http://dbpedia.org/property/n
|
1712
|
| http://dbpedia.org/property/o
|
1988
|
| http://dbpedia.org/property/s
|
52
|
| http://dbpedia.org/property/source
|
u
|
| http://dbpedia.org/property/synonyms
|
KHK4827, AMG 827
|
| http://dbpedia.org/property/target
|
http://dbpedia.org/resource/Interleukin_17_receptor_A +
|
| http://dbpedia.org/property/tradename
|
Siliq, Kyntheum, Lumicef
|
| http://dbpedia.org/property/type
|
mab
|
| http://dbpedia.org/property/unii
|
6
|
| http://dbpedia.org/property/verifiedfields
|
changed
|
| http://dbpedia.org/property/verifiedrevid
|
459982905
|
| http://dbpedia.org/property/watchedfields
|
changed
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Monoclonals_for_immune_system +
, http://dbpedia.org/resource/Template:Drugbankcite +
, http://dbpedia.org/resource/Template:Antineoplastic-drug-stub +
, http://dbpedia.org/resource/Template:Monoclonal-antibody-stub +
, http://dbpedia.org/resource/Template:Fdacite +
, http://dbpedia.org/resource/Template:Drugbox +
, http://dbpedia.org/resource/Template:Portal_bar +
, http://dbpedia.org/resource/Template:Cite_web +
, http://dbpedia.org/resource/Template:Interleukin_receptor_modulators +
, http://dbpedia.org/resource/Template:Cascite +
, http://dbpedia.org/resource/Template:Chemspidercite +
, http://dbpedia.org/resource/Template:Redirect +
, http://dbpedia.org/resource/Template:Keggcite +
, http://dbpedia.org/resource/Template:Reflist +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Amgen +
|
| http://purl.org/linguistics/gold/hypernym
|
http://dbpedia.org/resource/Antibody +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Brodalumab?oldid=1124010770&ns=0 +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Brodalumab +
|
| owl:sameAs |
http://rdf.freebase.com/ns/m.0h561_2 +
, http://www.wikidata.org/entity/Q4972934 +
, http://or.dbpedia.org/resource/%E0%AC%AC%E0%AD%8D%E0%AC%B0%E0%AD%8B%E0%AC%A1%E0%AC%BE%E0%AC%B2%E0%AD%81%E0%AC%AE%E0%AC%BE%E0%AC%AC +
, http://yago-knowledge.org/resource/Brodalumab +
, http://cs.dbpedia.org/resource/Brodalumab +
, http://ru.dbpedia.org/resource/%D0%91%D1%80%D0%BE%D0%B4%D0%B0%D0%BB%D1%83%D0%BC%D0%B0%D0%B1 +
, http://fr.dbpedia.org/resource/Brodalumab +
, https://global.dbpedia.org/id/4caiE +
, http://ar.dbpedia.org/resource/%D8%A8%D8%B1%D9%88%D8%AF%D8%A7%D9%84%D9%88%D9%85%D8%A7%D8%A8 +
, http://dbpedia.org/resource/Brodalumab +
|
| rdf:type |
http://dbpedia.org/class/yago/MonoclonalAntibody115029781 +
, http://dbpedia.org/ontology/ChemicalSubstance +
, http://dbpedia.org/class/yago/PhysicalEntity100001930 +
, http://dbpedia.org/class/yago/Part113809207 +
, http://dbpedia.org/class/yago/Matter100020827 +
, http://dbpedia.org/class/yago/Protein114728724 +
, http://dbpedia.org/class/yago/OrganicCompound114727670 +
, http://dbpedia.org/class/yago/Material114580897 +
, http://dbpedia.org/class/yago/Macromolecule114944888 +
, http://dbpedia.org/class/yago/Relation100031921 +
, http://dbpedia.org/class/yago/Molecule114682133 +
, http://dbpedia.org/class/yago/Unit109465459 +
, http://dbpedia.org/class/yago/Compound114818238 +
, http://dbpedia.org/class/yago/Chemical114806838 +
, http://dbpedia.org/class/yago/Substance100019613 +
, http://dbpedia.org/class/yago/Thing100002452 +
, http://dbpedia.org/class/yago/Antibody115027189 +
, http://dbpedia.org/class/yago/Abstraction100002137 +
, http://www.wikidata.org/entity/Q8386 +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#ChemicalObject +
, http://dbpedia.org/ontology/Drug +
, http://dbpedia.org/ontology/MonoclonalAntibody +
, http://dbpedia.org/class/yago/WikicatMonoclonalAntibodies +
|
| rdfs:comment |
Brodalumab, sold under the brand name Sili … Brodalumab, sold under the brand name Siliq in the US and Kyntheum in the EU, is a human monoclonal antibody designed for the treatment of inflammatory diseases. In February 2017, it received US FDA approval to treat moderate to severe plaque psoriasis in people who have not improved with other treatments.o have not improved with other treatments.
, Le brodalumab est un anticorps monoclonal … Le brodalumab est un anticorps monoclonal ciblant le récepteur A de l'interleukine 17 (IL-17RA). Il agit comme antagoniste des récepteurs à l'IL-17 comparativement aux autres inhibiteurs de l'IL-17, qui eux vont agir sur l'IL-17 et non sur son récepteur en la neutralisant. Il est aujourd'hui approuvé dans différentes juridictions dans le traitement du psoriasis modéré à sévère.e traitement du psoriasis modéré à sévère.
, برودالوماب هو جسم مضاد وحيد النسيلة مصمم لعلاج أمراض التهابية طورته آمجن.
, Brodalumab (v USA pod názvem Siliq, v Evropě Kyntheum) je lidská monoklonální protilátka určená k léčbě zánětlivých onemocnění.V únoru 2017 byl Brodalumab schválen FDA pro léčbu středně těžké až těžké (lupénky) u lidí, jejichž předchozí léčba selhala.
, Бродалумаб (brodalumab) — лекарственный препарат, моноклональное антитело. Одобрен для применения: США (февраль 2017 года).
|
| rdfs:label |
Brodalumab
, Бродалумаб
, برودالوماب
|
